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Pre–B cells undergo apoptosis unless they are rescued by pre–B cell receptor–dependent 
survival signals. We previously showed that the BCR-ABL1 kinase that is expressed in pre–B 
lymphoblastic leukemia bypasses selection for pre–B cell receptor–dependent survival signals. 
Investigating possible interference of BCR-ABL1 with pre–B cell receptor signaling, we found 
that neither SYK nor SLP65 can be phosphorylated in response to pre–B cell receptor 
engagement. Instead, Bruton’s tyrosine kinase (BTK) is constitutively phosphorylated by 
BCR-ABL1. Activated BTK is essential for survival signals that otherwise would arise from the 
pre–B cell receptor, including activation of PLC
 

 
1, autonomous Ca
 
2
 

 
 signaling, STAT5-
phosphorylation, and up-regulation of 
 
BCLX
 
L
 
. Inhibition of BTK activity specifically induces 
apoptosis in 
 
BCR-ABL1
 

 
 leukemia cells to a similar extent as inhibition of BCR-ABL1 kinase 
activity itself. However, BCR-ABL1 cannot directly bind to full-length BTK. Instead, 
BCR-ABL1 induces the expression of a truncated splice variant of BTK that acts as a linker 
between the two kinases. As opposed to full-length BTK, truncated BTK lacks kinase activity 
yet can bind to BCR-ABL1 through its SRC-homology domain 3. Acting as a linker, truncated 
BTK enables BCR-ABL1–dependent activation of full-length BTK, which initiates downstream 
survival signals and mimics a constitutively active pre–B cell receptor.
 
The 
 
BCR-ABL1
 
 gene rearrangement encodes a
constitutively active tyrosine kinase and drives
malignant transformation of pre–B cells in hu-
mans (1). In a B cell–specific mouse model,
expression of 
 
BCR-ABL1
 
 is sufficient to induce
pre–B lymphoblastic leukemia and is required for
maintenance of leukemic transformation (2).
During their development, human B cells
have to pass multiple checkpoints at which
they are selected for the expression of a func-
tional pre–B or B cell receptor (3). However,
signals from the pre–B cell receptor also may
initiate apoptosis (4). Therefore, the expression
of a functional pre–B cell receptor constitutes
an effective means to regulate tightly the sur-
vival or elimination of individual B cell clones.
In this regard, it is not surprising that in several
B cell–derived malignancies, pre–B or B cell
receptor function is compromised (5). For in-
stance, Hodgkin and Reed-Sternberg cells in
classic Hodgkin’s disease carry “crippled” Ig
variable region gene rearrangements as a result
of the acquisition of deleterious somatic muta-
tions (6). Likewise, transformation of human B
cells by the EBV mimics antigen receptor–
dependent survival signals through the viral
oncoprotein LMP2A, and prevents the B cell
receptor from signaling by excluding it from
glycolipid-enriched membrane domains (7).
Autonomous growth and survival of trans-
formed B cells seem to favor a situation in
which the B cell receptor is not active. In accor-
dance with this notion, we recently observed
that pre–B lymphoblastic leukemia clones har-
boring a 
 
BCR-ABL1
 
 fusion gene carry only
nonproductively rearranged Ig variable region
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genes in 9 of 12 cases (8). Even the few leukemia clones that
do express a pre–B cell receptor were not responsive to
pre–B cell receptor engagement (8). Analogous to the
EBV-encoded LMP2A protein, the expression of the onco-
genic BCR-ABL1 kinase may confer autonomous survival
signals, and interfere with antigen receptor signaling.
Among others, Bruton’s tyrosine kinase (BTK) repre-
sents a crucial component of the (pre)-B cell receptor signal-
ing chain and links the (pre)-B cell receptor to Ca
 
2
 

 
 signals
in B lymphoid cells (9). In humans, deficiency of BTK leads
to X-linked agammaglobulinemia which results from a dif-
ferentiation block at the pre–B cell–stage (10). Of note,
BTK promotes developmental progression of pre–B cells
(11), and acts as a tumor suppressor to prevent pre–B lym-
phoblastic leukemia in mice (12, 13). To elucidate how
BCR-ABL1 can bypass selection for pre–B cell receptor–
dependent survival signals, the current study investigates
possible interference of BCR-ABL1 with pre–B cell recep-
tor–related signaling molecules, including spleen tyrosine ki-
nase (SYK), SLP65, phospholipase C 
 

 
 (PLC
 

 
)2, and BTK.
 
RESULTS
BCR-ABL1 kinase activity induces tyrosine-phosphorylation 
of BTK
 
Normal pre–B cells can survive in human bone marrow only
if they receive survival signals through their pre–B cell re-
ceptor (14). In a previous study, we observed that in the ma-
jority of cases of pre–B lymphoblastic leukemia expressing
the oncogenic BCR-ABL1 kinase, the leukemia cells do not
harbor a functionally rearranged 
 
IGH
 
 allele, and hence, can-
not express a pre–B cell receptor on their surface (8). There-
fore, we wondered how a pre–B cell–derived leukemia cell
can survive and even clonally expand in the absence of pre–B
cell receptor–dependent survival signals.
To determine if BCR-ABL1 interferes with signal trans-
duction of the pre–B cell receptor, we examined whether the
pre–B cell receptor–related signaling molecules SYK, SLP65,
and BTK are expressed and if they can be phosphorylated
upon pre–B cell receptor engagement in the leukemia cells.
Western blot using antibodies against phosphorylated
SYK
 
Y323
 
, SLP65
 
Y96
 
, and BTK
 
Y223
 
 showed that neither SYK
nor SLP65 was phosphorylated in response to cross-linking
of the pre–B cell receptor (unpublished data). However,
BTK was constitutively phosphorylated in the leukemia cells
(at 77 kD; Fig. 1 A).
Using a specific inhibitor of BCR-ABL1, termed STI571
(15), we found that phosphorylation of BTK was sensitive to
inhibition of BCR-ABL1 kinase activity (77kD; Fig. 1 A). To
determine whether constitutive phosphorylation of 77-kD
BTK is specific for leukemia cells that carry a 
 
BCR-ABL1
 
gene rearrangement, BTK phosphorylation also was studied in
pre–B lymphoblastic leukemias that harbored an 
 
E2A-PBX1
 
,
 
MLL-AF4
 
, 
 
TEL-AML1
 
, or 
 
TEL-PDGFR
 

 
 gene rearrange-
ment (Fig. 1 B, Table I). Although the BTK
 
Y223
 
-specific anti-
body detected smaller tyrosine-phosphorylated proteins also in
other leukemias, constitutive Y223 phosphorylation of BTK
(77 kD) was specific for 
 
BCR-ABL1
 

 
 pre–B cell lymphoblas-
tic leukemia cell lines (Fig. 1 B, left).
To confirm that BTK phosphorylation is dependent on
BCR-ABL1 kinase activity, we induced BCR-ABL1 expres-
sion in a murine B lymphoid cell line TONB210 (16) that car-
ries an inducible 
 
BCR-ABL1
 
 transgene. As opposed to 
 
BCR-
ABL1
 

 
 leukemia cells, this cell line grows independently from
BCR-ABL1 in the presence of IL-3. In the presence, but not
in the absence, of doxycycline-induced BCR-ABL1 expres-
sion, BTK was heavily phosphorylated (see Fig. 5 C). We con-
clude that BTK is constitutively phosphorylated by BCR-
ABL1, but not by the pre–B cell receptor in the leukemia cells.
 
BTK phosphorylation depends on BCR-ABL1 kinase 
activity in vivo
 
To confirm that phosphorylation of BTK also depends on
BCR-ABL1 kinase activity in primary leukemia cells, expres-
Figure 1. BCR-ABL1 induces phosphorylation of BTK in pre–B 
lymphoblastic leukemia cells. Protein expression and tyrosine phos-
phorylation of the pre–B cell receptor downstream signaling molecules 
SYK, SLP65, and BTK was studied by Western blot in three BCR-ABL1 
pre–B lymphoblastic leukemia cell lines (VII, VIII, and IX in Table I) in the 
presence or absence of STI571. The BTKpY223 antibody detected full-length 
BTK (77 kD) as well as two additional tyrosine phosphorylated proteins of 
65-kD and 52-kD size (A–C). To confirm that constitutive phosphorylation 
of 77-kD full-length BTK is specific for BCR-ABL1 kinase activity, BTKY223-
phosphorylation was studied in four BCR-ABL1–negative B cell precursor 
cell lines (B, left panel; see XI, XII, XIII, and XV in Table I). Dependence of 
BTK on BCR-ABL1 kinase activity also was confirmed in four primary cases 
of BCR-ABL1 pre–B lymphoblastic leukemia, from which matched sample 
pairs before and during therapy with STI571 were available (B, right panel; 
cases I to IV in Table I). EIF-4E was used as a loading control. To determine 
whether Y223 phosphorylation of BTK is mediated by transphosphorylation 
through BCR-ABL1 or autophosphorylation, BCR-ABL1 leukemia cells 
(IX; Table I) were treated for 24 h with the BCR-ABL1 kinase inhibitor, 
STI571, or the BTK inhibitor, LFM-A13 (C).
 JEM VOL. 201, June 6, 2005
 
1839
 
ARTICLE
 
sion of tyrosine-phosphorylated BTK was compared in
matched leukemia sample pairs from four patients before and
during continued therapy with STI571 (cases I to IV, Fig. 1
B, right panel). The content of 
 
BCR-ABL1
 

 
 leukemia cells
was similar in the samples taken before and during STI571
treatment as assessed by semiquantitative amplification of
 
BCR-ABL1
 
 fusion transcripts (see Fig. 2 A). As with inhibi-
tion of BCR-ABL1 kinase by STI571 in vitro, in vivo abla-
tion of BCR-ABL1 kinase activity resulted in the loss of BTK
phosphorylation in all four patients (Fig. 1 B, right panel).
 
Table I.
 
Description of leukemia and lymphoma cases and cell lines studied
 
Translocation IGH configuration
Case Age Sex Fusion gene IgH
Ig
 

 
/
 

 
or SLC Alleles Coding capacity Clinical course
 
I
 
a
 
39 m
 
BCR-ABL1
 
; p210 – – (1) V
 
H
 
4.34-D
 
H
 
6.13-J
 
H
 
5
(2) D
 
H
 
5-J
 
H
 
no; out-of-frame ALL, relapse after STI571 treatment
II
 
a
 
54 f
 
BCR-ABL1
 
; p190 – – (1) V
 
H
 
4.61-D
 
H
 
2.2-J
 
H
 
4
(2)D
 
H
 
2.4-J
 
H
 
4
no; out-of-frame,
stop in junction
ALL, relapse after STI571 treatment
III
 
a
 
61 f
 
BCR-ABL1
 
; p190 ND ND ND – ALL, relapse after STI571 treatment
IV
 
a
 
47 f
 
BCR-ABL1
 
; p190 ND ND ND – ALL, relapse after STI571 treatment
V
 
a
 
34 m
 
BCR-ABL1
 
; p190 – – (1) V
 
H
 
4.34-D
 
H
 
6.13-J
 
H
 
5
(2) D
 
H
 
5-J
 
H
 
out-of-frame ALL, complete remission after BMT
VI
 
a
 
32 m
 
BCR-ABL1
 
; p190 – – (1) V
 
H
 
4.4-D
 
H
 
2.2-J
 
H
 
4
(2) D
 
H
 
2.4-J
 
H
 
4
out-of-frame,
stop codons in junction
ALL, died after BMT
VII
 
a
 
45 m
 
BCR-ABL1
 
; p210 – – (1) V
 
H
 
3.48-D
 
H
 
2.15-J
 
H
 
3
(2) D
 
H
 
2-J
 
H
 
no; out-of-frame,
stop in junction
ALL, died after relapse
(BV173 cell line)
VIII
 
a
 
3 f
 
BCR-ABL1
 
; p210
 

 
 chain SLC (1) D
 
H
 
4-J
 
H
 
(2) V
 
H
 
3.9-D
 
H
 
2.21-J
 
H
 
3
no
yes
ALL, died after relapse
(NALM1 cell line)
IX
 
a
 
9 m
 
BCR-ABL1
 
; p190
 

 
 chain SLC (1) V
 
H
 
3.53-D
 
H
 
2.8-J
 
H
 
6 yes
 
b
 
ALL, died after relapse
(SUP-B15 cell line)
X 32 f
 
MLL-AF4
 
– – (1) V
 
H
 
3.20-D
 
H
 
2.8-J
 
H
 
5
(2) V
 
H
 
6.1-D
 
H
 
1.7-J
 
H
 
4
no; out-of-frame
no; stop in junction
ALL, relapse after chemotherapy
(RS4;11 cell line)
XI 5 f
 
MLL-AF4
 
– – (1) D
 
H
 
3-J
 
H
 
(2) 
 
IGH
 
 in germline
no ALL, relapse after chemotherapy
(SEM cell line)
XII 15 f
 
TEL-AML1
 
– – (1) V
 
H
 
3.15-D
 
H
 
3.10-J
 
H
 
6
(2) 
 
IGH
 
 in germline
no; out-of-frame ALL, relapse after chemotherapy
(REH cell line)
XIII 12 m
 
E2A-PBX1
 

 
 chain SLC (1) V
 
H
 
4.34-D
 
H
 
3.22-J
 
H
 
2
(2) VH2.26-DH2.2-JH4
no; out-of-frame,
stop in junction
yes
ALL, relapse after chemotherapy
(697 cell line)
XIV 15 m E2A-PBX1  chain SLC (1) VH3.7-DH3.10-JH4 yesb ALL, cell line
(KASUMI-2) established at diagnosis
XV 19 m TEL-PDGFR  chain SLC (1) VH1.69-DH3.10-JH6 yesb ALL, relapse after chemotherapy 
(NALM6 cell line)
XVI 5 m IGH-MYC IgM Ig (1) VH3.53-DH3.3-JH6
(2) VH4.34-DH2.15-JH5
no; stop in junction
yes
Burkitt’s lymphoma cell line
(MHH-PREB1) established at diagnosis
XVII 73 f IGH-BCL2 IgG Ig (1) VH4.39-DH3.10-JH6c
(2) VH3.9-DH3.22-JH6c
(3) VH3.23-DH6.13-JH5c
yes
no; out-of-frame
no; out-of-frame
Diffuse large B cell lymphoma cell line
(KARPAS-422) established at diagnosis
aThese cases were described in Klein et al. (reference 8).
bThe second IGH allele was not subjected to sequence analysis if a potentially functional allele was already amplified.
cThree IGH VDJ gene rearrangements are compatible with three chromosome 14s in these B cell lymphoma cells. Alternatively, the cell line may comprise subclones with differ-
ent IGH VDJ gene rearrangements.
ALL, acute lymphoblastic leukemia; n.d., not done;  SLC, surrogate light chain.
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Figure 2. BCR-ABL1 induces expression of kinase-deficient BTK 
isoforms. Comparing matched leukemia sample pairs taken before and 
during continued therapy with the BCR-ABL1 kinase-inhibitor, STI571, BTK 
transcripts, including splice variants (BTKp52and BTKp65), were amplified 
(A, top). cDNA samples were normalized for equal content of leukemia 
cells by amplification of BCR-ABL1 (A, bottom). To determine whether 
aberrant splicing of BTK is induced by BCR-ABL1, pre–B lymphoblastic 
leukemia cells carrying an E2A-PBX1—but no BCR-ABL1 rearrangement—
were transiently transfected with a retroviral expression vector which 
encoded BCR-ABL1 and GFP, or GFP alone (B). GFP and GFP cells were 
sorted after 24 h (B, top) and subjected to RT-PCR analysis. cDNA amounts 
were normalized by amplification of a GAPDH fragment (B, bottom). In 
addition to full-length BTK, sequence analysis of BTK transcripts revealed 
six isoforms (Table S2). Among these isoforms, two were recurrently 
amplified: BTKp52 and BTKp65 were detected in all nine cases of BCR-ABL1 
pre–B lymphoblastic leukemia studied (C). Both isoforms carry a deletion 
within their kinase domain. Skipping of exon 15 (BTKp52) leads to the loss 
of the reading frame and COOH-terminal truncation as the result of a pre-
mature translation stop at codon 442 (C, middle). BTKp65 lacks exons 15 
and 16 and leads to an in-frame deletion of 282 bp (BTKp65).
JEM VOL. 201, June 6, 2005 1841
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BTKY223 can be transphosphorylated by BCR-ABL1
To clarify further BCR-ABL1–dependent phosphorylation
of BTKY223, we investigated whether phosphorylation at
Y223 depends only on BCR-ABL1 or also on endogenous
BTK activity. In normal B cells, B cell receptor engage-
ment leads first to LYN-mediated transphosphorylation of
COOH-terminal BTKY551 (17). BTKY223 phosphorylation
occurs as a secondary event by autophosphorylation through
endogenous BTK activity (17). Therefore, the effect of the
BTK inhibitor, LFM-A13, on BTKY223 phosphorylation in
BCR-ABL1 pre–B cell lymphoblastic leukemia cells was
examined. BTKY223 phosphorylation was sensitive to BCR-
ABL1 kinase inhibition by STI571, but not to BTK inhibi-
tion by LFM-A13 (Fig. 1 C). We conclude that BTKY223 is
accessible to transphosphorylation by BCR-ABL1 in the ab-
sence of endogenous BTK activity.
Expression of truncated BTK splice variants in BCR-ABL1 
pre–B lymphoblastic leukemia
In the BTK Western blot analysis of BCR-ABL1 pre–B
lymphoblastic leukemia cell lines, we observed that the anti-
body that recognized phosphorylated BTKY223 at the ex-
pected size of 77 kD also detected two smaller tyrosine-
phosphorylated proteins of 65 kD and 52 kD in size (Fig.
1, A–C). This prompted us to investigate splice variants of
BTK at the mRNA level.
By amplifying specific BTK cDNA fragments that cover
the entire coding region of BTK, we detected shorter PCR
products in all three BCR-ABL1 pre–B lymphoblastic leu-
kemia cell lines (not depicted) and also in six primary cases of
BCR-ABL1 pre–B lymphoblastic leukemia (cases I to VI,
Table I; Fig. 2 A).
In total, sequence analysis revealed six different BTK iso-
forms in BCR-ABL1 pre–B lymphoblastic leukemia cells
(Table S2, available at http://www.jem.org/cgi/content/
full/jem.20042101/DC1; sequence data available from
GenBank/EMBL/DDBJ under accession nos. AJ888376–
AJ888381). All of these splice variants carry large deletions
within the kinase domain (Table S2). Four of these isoforms
were unique, were generated by usage of cryptic splice sites,
and only were amplified from individual cases of BCR-
ABL1 pre–B lymphoblastic leukemia. However, two BTK
isoforms were identified recurrently.
In addition to a previously described BTK isoform which
lacks exons 15 and 16 (BTKp65 in Fig. 2 A; reference 18),
another truncated splice variant that lacks only exon 15 was
amplified from all nine cases of BCR-ABL1 pre–B lym-
phoblastic leukemia (Table S2). Joint skipping of exons 15
(217 bp) and 16 (65 bp) leads to an in-frame 282-bp deletion
(BTKp65; Fig. 2 C). The predicted size of the protein en-
coded by BTKp65 matches the 65-kD protein recognized by
the BTKY223 antibody (Fig. 1, A–C). Skipping of exon 15
alone leads to loss of the reading frame and generates a pre-
mature stop codon which results in the expression of a trun-
cated protein of 442 amino acids instead of 659 amino acids
(BTKp52; Fig. 2 C). The predicted truncated BTKp52 (442
amino acids) exactly matches the size of the heavily phos-
phorylated 52-kD protein that we detected with the phos-
pho-specific anti-BTKY223 antibody (Fig. 1, A–C).
By comparing matched sample pairs of leukemia cells be-
fore and during continued therapy with the BCR-ABL1 ki-
nase inhibitor, STI571, we amplified BTKp52 (lacking exon
15 alone) or BTKp65 (lacking exons 15 and 16) in the pres-
ence (but not in the absence) of BCR-ABL1 kinase activity
(Fig. 2 A). These findings suggest that aberrant splicing of
BTK may be linked to BCR-ABL1 kinase activity.
BCR-ABL1 was implicated previously in altered splice-
site selection and exon skipping through up-regulation of
RNA-binding proteins, including FUS, hnRNP A1, and
hnRNP E2 (19). In addition, a recent study shows that
Figure 3. Specific silencing of full-length BTK or BTK splice variants 
by RNA interference. BCR-ABL1 pre–B lymphoblastic leukemia cells 
were transfected with a nontargeting siRNA duplex in the presence or 
absence of STI571 (for 12 h), as well as with a mixture of siRNAs against 
full-length BTK, BTKp52, or BTKp65. All siRNA duplices were labeled with 
fluorescein before transfection. Transfection was repeated after 24 h, and 
105 cells carrying fluorescein-labeled siRNAs (between 3–5% of all viable 
cells) were sorted by FACS 48 h after the first transfection (upper panel). 
Total RNA was isolated and subjected to semiquantitative RT-PCR analysis 
of BTK isoform expression (lower panel). mRNA levels for HPRT and COX6B 
(see Fig. 8 C) were stable under all conditions.
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Figure 4. Inhibition of BTK induces apoptosis specifically in BCR-
ABL1 pre–B lymphoblastic leukemia cells. BCR-ABL1–negative B lym-
phoid leukemia and lymphoma cell lines (A, left panel) and two BCR-ABL 
leukemia cell lines (A, middle and right panel) were incubated for the times 
indicated under control conditions, with STI571 (solid line) or with the BTK 
inhibitor, LFM-A13 (dashed line; A). Relative viability (percent living cells) 
was calculated as the ratio of viability in the presence of STI571 or LFM-A13 
and viability in untreated cells. Two BCR-ABL1 and eight BCR-ABL1–negative 
B lymphoid cell lines were incubated in the presence of LFM-A13 or under 
control conditions for 114 h (B). Relative survival of the treated cells as 
compared with control conditions is given as the mean of three independent 
experiments  SD. To analyze BCR-ABL1–mediated and BTK-dependent 
JEM VOL. 201, June 6, 2005 1843
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BCR-ABL1 induces aberrant splicing of PYK2 premRNA
in human hematopoietic progenitor cells, which can be re-
verted by STI571 (20). These findings exemplify that
BCR-ABL1 frequently interferes with normal regulation of
premRNA splicing (e.g., by reduction of stringency of
splice-site selection).
To assess directly whether BCR-ABL1 can interfere with
splicing of BTK premRNA, we transiently transfected pre–B
lymphoblastic leukemia cells that carry an E2A-PBX1, but no
BCR-ABL1, gene rearrangement with an expression vector
which encodes GFP only or GFP and BCR-ABL1. For both
transfections, GFP and GFP cells were sorted and analyzed
separately for expression of BTK splice variants (Fig. 2 B). Al-
though E2A-PBX1 pre–B lymphoblastic leukemia cells un-
der control conditions express BTKp65 at low levels, induced
expression of BCR-ABL1 leads to the expression of multiple
BTK splice variants (Table S2), including BTKp52 (Fig. 2 B).
We conclude that BCR-ABL1 induces aberrant splicing of
BTK and expression of BTKp52.
By comparing 19 genome-wide gene expression profiles
by serial analysis of gene expression (SAGE), we identified
three SAGE-tags that distinguish between full-length
BTK, BTKp65, and BTKp52 (Table S3, available at http://
www.jem.org/cgi/content/full/jem.20042101/DC1). A
SAGE-tag represents a 14-bp cDNA sequence which imme-
diately flanks the extreme 3	 restriction site (CATG) of the
tagging enzyme (NlaIII) that is used as a unique identifier of
any processed transcript. Although full-length BTK is ex-
pressed widely in normal B cell populations and BTKp65 also
is expressed in non–BCR-ABL1 B lymphoid malignancies,
BTKp52 seems to be expressed specifically in BCR-ABL1
leukemia cells (Table S3).
Specific silencing of BTK splice variants by RNA interference
To investigate the function of full-length BTK and its splice
variants in BCR-ABL1 pre–B lymphoblastic leukemia cells,
we established an RNA interference approach to silence full-
length BTK and BTK isoforms specifically. Among the six
BTK splice variants (Table S2), only BTKp52 and BTKp65
were amplified recurrently. Therefore, we focused our anal-
ysis on BTKp52 and BTKp65. To clarify the specific function
of BTKp52 (lack of exon 15, loss of reading frame) and
BTKp65 (in-frame deletion of exons 15 and 16), we designed
three small interfering RNA (siRNA) duplices against the
junction of BTK exons 14 and 16 (corresponding to
BTKp52) and the junction of BTK exons 14 and 17 (corre-
sponding to BTKp65). For each target, the three siRNA du-
plices were mixed and fluorescein labeled. Also for full-
length BTK, three siRNA duplices were synthesized (specif-
ically binding to BTK exon 15), mixed, and fluorescein
labeled. As a control, a fluorescein-labeled nontargeting
siRNA duplex was used. After two transfections, the pro-
portion of siRNA-carrying cells ranged between 3% and 5%
(Fig. 3). For each condition, 105 fluorescein cells were
sorted and subjected to RT-PCR analysis for BTK splice
variants. mRNA levels of the reference genes HPRT and
COX6B remained unchanged (Fig. 3; see Fig. 8). Sorted
cells exhibited specific silencing of full-length BTK, BTKp52,
or BTKp65, and no cross-inhibition of BTK isoform expres-
sion was observed (Fig. 3). Because lymphoid cells typically
are difficult to transfect, we conclude that double transfec-
tion of a mixture of three siRNA duplices and cell sorting of
siRNA-carrying cells represents an effective strategy to si-
lence specifically target mRNA sequences in B lymphoid
leukemia cells.
From in vitro kinase assays of BTK mutants that were
derived from BTK-deficient patients who had X-linked
agammaglobulinemia, it is known that even replacement
mutations in the distal portion of the kinase domain result
in a complete loss of BTK activity (http://bioinf.uta.fi/
BTKbase/BTKbasebrowser.html). Hence, only full-length
BTK—but none of the BTK splice variants identified here—
should exhibit BTK activity. Therefore, we investigated the
relevance of BTK activity for BCR-ABL1–mediated sur-
vival signaling in pre–B lymphoblastic leukemia cells.
Inhibition of BTK activity induces apoptosis specifically in 
human BCR-ABL1 pre–B lymphoblastic leukemia cells
To clarify the role of full-length BTK (as compared with ki-
nase-deficient truncated BTK) in pre–B lymphoblastic leu-
kemia cells, we analyzed the effect of BTK inhibition on the
survival of BCR-ABL1 leukemia cells in comparison with
inhibition of BCR-ABL1 by STI571. As a control we used
several B lymphoid cell lines that do not carry a BCR-ABL1
gene rearrangement. Neither inhibition of endogenous
c-ABL1 (by STI571) nor BTK (by LFM-A13) kinase activ-
ity alone significantly reduced viability of BCR-ABL1–nega-
tive B lymphoid cells (Fig. 4 A, B). Conversely, inhibition of
BCR-ABL1 rendered almost all BCR-ABL1 pre–B lym-
phoblastic leukemia cells apoptotic within 5 d (Fig. 4 A). In
both BCR-ABL1 pre–B lymphoblastic leukemia cell lines
that were tested, but not in BCR-ABL1–negative cell lines,
tyrosine phosphorylation of STAT5 (C), three BCR-ABL1 B cell precursor 
cell lines (VII, VIII, and IX in Table I) were treated with the BCR-ABL1 kinase 
inhibitor, STI571 (dotted line), with the BTK inhibitor, LFM-A13 (solid line), 
or incubated under control conditions (shaded areas; C). Nuclear localization 
of activated STAT5 in treated and untreated leukemia cells was visualized by 
confocal laser microscopy (C; red stain, middle). BCR-ABL1 pre–B lym-
phoblastic leukemia cells were transfected with a mixture of fluorescein-
labeled siRNAs against full-length BTK as shown in Fig. 3. Fluorescein 
cells carrying siRNA molecules (green) were stained for tyrosine-phosphor-
ylated STAT5 (red) and analyzed by confocal laser microscopy (C, bottom 
panel). As a negative control, nontargeting siRNA duplices were used. 
Next, mRNA levels of BCLXL were studied in BCR-ABL1 pre–B lympho-
blastic leukemia cells in the presence or absence of STI571 or LFM-A13. 
Total RNA was isolated from the leukemia cells and subjected to semi-
quantitative RT-PCR analysis for mRNA levels of BCLXL (D). cDNA amounts 
were normalized by amplification of a GAPDH cDNA fragment.
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inhibition of BTK had a very similar effect as inhibition of
BCR-ABL1, and also induced apoptosis in 90 percent of
the leukemia cells within 5 d (Fig. 4 A, B). These findings
are in agreement with an RNA interference experiment that
showed that silencing of full-length BTK expression (Fig. 3)
induced apoptosis in BCR-ABL1 pre–B lymphoblastic leu-
kemia cells (see Fig. 8 A). Thus, BTK activity is required for
sustained growth and survival of BCR-ABL1–transformed
human pre–B lymphoblastic leukemia cells.
BCR-ABL1–induced tyrosine phosphorylation and nuclear 
localization of STAT5 requires BTK activity
Besides other survival signals, STAT5 activation is critical for
BCR-ABL1–mediated transformation (21, 22). Given that
BTK activity can activate STAT5 through phosphorylation
at tyrosine 694 (23), we investigated the impact of BCR-
ABL1 or BTK inhibition on STAT5Y694 phosphorylation in
three BCR-ABL1 pre–B lymphoblastic leukemia cell lines
by intracellular staining and flow cytometry. STAT5Y694 is
Figure 5. BTK links BCR-ABL1 to PLC1-mediated Ca2 signals in 
pre–B lymphoblastic leukemia cells. Cytoplasmic Ca2 levels were mea-
sured in single leukemia cells by confocal laser microscopy. Before Ca2 
measurement, cells were kept under control conditions or treated for 24 h 
with STI571 or LFM-A13 (A). Pre–B cell receptor engagement by addition 
of -heavy chain–specific antibodies (arrows) did not change cytoplasmic 
Ca2 concentrations. Although PLC1Y783 is phosphorylated in the presence—
but not in the absence ( STI571)—of BCR-ABL1 kinase activity (B, left 
panels), PLC2 was not tyrosine phosphorylated by BCR-ABL1 (not de-
picted). As a control for nonspecific side effects of STI571, murine B lym-
phoid cells carrying a doxycycline-inducible BCR-ABL1 transgene were 
analyzed in the presence or absence of 1 g/ml doxycycline (DOX). These 
cells remain viable in the absence of BCR-ABL1 expression if the cell culture 
fluid is supplemented with 2 ng/ml murine recombinant IL-3. Protein extracts 
from these cells were subjected to Western blot using human- and 
mouse-reactive antibodies (B, right). Tyrosine phosphorylation of PLC1 was 
studied in BCR-ABL1 pre–B lymphoblastic leukemia cells in the presence or 
absence of STI571 or LFM-A13. EIF-4E was used as a loading control in 
both Western blots (B, C). Expression of full-length BTK was silenced by 
RNA interference in a BCR-ABL1 pre–B lymphoblastic leukemia cell line 
(IX in Table I). Sorted cells carrying fluorescein-labeled siRNAs (green) were 
permeabilized, stained for PLC1pY783 (red), and analyzed by confocal laser 
microscopy (C, bottom). As a negative control, nontargeting siRNA duplices 
were used. BCR-ABL1–binding proteins were coimmunoprecipitated using 
an antibody against BCR. The immunoprecipitation was controlled by a 
Western blot using an ABL1-specific antibody (D).
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constitutively phosphorylated in all three leukemia cell lines
and exhibits nuclear localization (Fig. 4 C), which is re-
quired for STAT5 activity (21, 22). However, ablation of
BCR-ABL1 kinase activity by STI571 and BTK inhibition
by LFM-A13 largely reduced phosphorylation and nuclear
localization of STAT5Y694 (Fig. 4 C).
In addition, three siRNA duplices against full-length
BTK were mixed, fluorescein labeled, and transfected into
BCR-ABL1 pre–B lymphoblastic leukemia cells (IX in Ta-
ble I) using fluorescein-labeled, nontargeting siRNAs as a
control. After two transfections, fluorescein leukemia cells
were sorted and analyzed for STAT5 phosphorylation (Fig. 4
C, lower panel). Efficiency and specificity of BTK full-length
silencing was controlled by RT-PCR (Fig. 3). In agreement
with BTK inhibition by LFM-A13, silencing of full-length
BTK by RNA interference largely attenuated STAT5Y694
phosphorylation as shown by confocal laser microscopy (Fig.
4 C) and intracellular FACS staining (see Fig. 8 B).
BTK-mediated transcriptional activation of BCLXL in 
BCR-ABL1 pre–B lymphoblastic leukemia cells
In BCR-ABL1 leukemia cells, STAT5 mainly accomplishes
its antiapoptotic effect by transcriptional activation of BCLXL
(24). By comparing the frequency of SAGE-tags that distin-
guish between antiapoptotic BCLXL and its proapoptotic
isoform, BCLXS, in 19 genome-wide SAGE-libraries, SAGE-
tags specific for BCLXL were particularly frequent in BCR-
ABL1 pre–B lymphoblastic leukemia cells (Table S3).
By analyzing mRNA levels for BCLXL in BCR-ABL1
pre–B lymphoblastic leukemia cells in the presence or ab-
sence of STI571 or LFM-A13, we found that inhibition of
BCR-ABL1 or BTK leads to a considerable reduction of
BCLXL expression in the leukemia cells (Fig. 4 D). This is
consistent with the effect of siRNA-mediated silencing of
full-length BTK on BCLXL mRNA levels (see Fig. 8 C).
A recent study identified SRC kinase activity as a re-
quirement for BCR-ABL1–mediated transformation of mu-
rine pre–B cells (25). The findings presented here indicate
that BTK activity also is required specifically for the BCR-
ABL1–dependent survival signals, and thus, may represent an
important target for the therapy of BCR-ABL1 pre–B lym-
phoblastic leukemia.
BTK activity is required for autonomous Ca2 signal activity 
in BCR-ABL1 pre–B lymphoblastic leukemia cells
In normal pre–B cells, BTK activity induces Ca2 release upon
pre–B cell receptor engagement through BTK-dependent
phosphorylation of PLC2. Constitutive phosphorylation of
BTK by BCR-ABL1 and specific requirement of BTK activity
for the survival of BCR-ABL1 leukemia cells suggest that
BCR-ABL1 also can trigger BTK-dependent Ca2 release
from cytoplasmic stores. In BCR-ABL1 pre–B lymphoblastic
leukemia cells that express a pre–B cell receptor on the surface
(Table I; reference 8), BCR-ABL1 kinase activity was linked to
an autonomous oscillatory Ca2 signal, which was not changed
by pre–B cell receptor engagement (arrows, left panel of Fig. 5
A). Analysis of Ca2 release in multiple pre–B lymphoblastic
leukemia cells at the single-cell level showed that inhibition of
BCR-ABL1 terminated the autonomous Ca2 signaling activ-
ity (Fig. 5 A, middle panel). Autonomous Ca2 signals required
BCR-ABL1 kinase activity and were abrogated by inhibition
of BTK activity through treatment with LFM-A13 (Fig. 5 A,
right panel). Comparing sorted fluorescein leukemia cells
which were transfected with full-length BTK-specific or non-
targeting siRNAs, autonomous oscillatory Ca2 signals were
Figure 6. COOH-terminally truncated BTK functions as a linker 
between full-length BTK and BCR-ABL1. Proteins binding to BCR-ABL1 
were coimmunoprecipitated with an anti–BCR antibody (A). Immunopre-
cipitation was controlled by an anti-ABL1–specific Western blot (WB) showing 
the characteristic BCR-ABL1 fusion protein expressed by the leukemia cell 
line. Proteins binding to full-length BTK were coimmunoprecipitated with 
an antibody against COOH-terminal BTK. Immunoprecipitation was con-
trolled by Western blot using an antibody against NH2-terminal BTK. Full-
length BTK and BTKp52 proteins coimmunoprecipitating with BCR-ABL1 or 
full-length BTK were visualized by Western blot using an antibody against 
NH2-terminal BTK (A). As a control for quantitative distribution of full-
length BTK and BTKp52 before coimmunoprecipitation with BCR-ABL1 or 
full-length BTK, WCLs were used (A). To analyze the effect of BTKp52 on 
BCR-ABL1–dependent phosphorylation of full-length BTK, BTKp52 expression 
was inhibited by RNA interference as described in Fig. 3. As a control, non-
targeting siRNA duplices were used. siRNAs were fluorescein-labeled and 
fluorescein cells were sorted and subjected to Western blot using anti-
bodies specific for tyrosine-phosphorylated BTKY223 (B). Because patterns 
of tyrosine phosphorylation varied between replicate experiments, Western 
blots of two representative experiments (Exp. 1 and 2) are shown. EIF4e 
was used as a loading control.
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diminished greatly in the leukemia cells that carried full-length
BTK-specific siRNAs (see Fig. 9 B).
Pre–B cell receptor–dependent Ca2 signals typically are
initiated by BTK-mediated phosphorylation of PLC2 (9).
Assuming that BCR-ABL1 targets downstream molecules of
the pre–B cell receptor signal cascade in BCR-ABL1 pre–B
lymphoblastic leukemia cells, we investigated whether BCR-
ABL1–dependent autonomous Ca2 signals also are trans-
Figure 7. BTKp52 facilitates BTK- and BCR-ABL1–dependent activa-
tion of PLC1 and STAT5 through its SH3 domain. BCR-ABL1, full-length 
BTK, BTKp52, and the SH3-domain of BTK were expressed in 293T embryonic 
kidney cells alone or in various combinations in the presence or absence of 
STI571 or LFM-A13. As a readout, cells were harvested, subjected to intracellu-
lar staining for tyrosine-phosphorylated PLC1 or STAT5, and analyzed by 
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flow cytometry (A). To visualize cytoplasmic localization of tyrosine-phos-
phorylated PLC1 and nuclear localization of activated STAT5, the stained 
cells also were subjected to analysis by confocal laser microscopy (B). 106 
293T cells were transfected transiently with full-length BTK for 24 h and sub-
jected to immunoprecipitation of full-length BTK. Immunoprecipitation (IP) 
was controlled by a BTK-specific Western blot (C). Kinase activity of immuno-
precipitated BTK was analyzed in an in vitro kinase assay using 150 ng of a 
PLC1 fragment (amino acids 530 to 850) as substrate. In parallel, 25 ng of 
recombinant active BTK and 100 ng of kinase-deficient SH3-domain of BTK 
were used in kinase assays as positive and negative controls, respectively.
duced by BTK and PLC2. Unexpectedly, PLC1—but not
PLC2 (not depicted)—is phosphorylated by BCR-ABL1 in
human leukemia cells (Fig. 5, B and C) and in mouse B lym-
phoid cells that carry an inducible BCR-ABL1 transgene
(Fig. 5 B). As shown by coimmunoprecipitation, BCR-
ABL1 does not bind directly to PLC1 (Fig. 5 D). Phosphor-
ylation of PLC1 was sensitive to inhibition of BTK by
LFM-A13 (Fig. 5 C) which indicates that PLC1 is activated
through BTK as in normal lymphocytes and not directly by
BCR-ABL1. Silencing of full-length BTK by RNA interfer-
ence using fluorescein-labeled full-length BTK-specific
siRNAs also results in a marked reduction of PLC1Y783
phosphorylation as assessed by confocal laser microscopy (Fig.
5 C) and intracellular FACS staining (see Fig. 9 A).
PLC1 contributes to survival signals in BCR-ABL1 
pre–B lymphoblastic leukemia cells
Whereas the role of STAT5 in BCR-ABL1–mediated sur-
vival signaling is well-established (21, 22, 24), a possible role
of PLC1 in the promotion of survival of BCR-ABL1 pre–B
lymphoblastic leukemia cells has not been investigated. To de-
termine whether BCR-ABL1– and BTK-dependent activa-
tion of PLC1 and PLC1-mediated Ca2 release contributes
to BCR-ABL1–mediated survival signals, we silenced PLC1
mRNA expression by RNA interference in three pre–B lym-
phoblastic leukemia cell lines that carry a BCR-ABL1 gene re-
arrangement (VII to IX, Table I) and four cell lines that carry
other chromosomal translocations (MLL-AF4, X; TEL-
AML1, XII; E2A-PBX1, XIII; TEL-PDGFRB, XV; Table I).
As a control, nontargeting siRNAs were used. Cells were
transfected twice with fluorescein-labeled siRNAs. To assess
viability, fluorescein cells were analyzed for propidium io-
dide uptake and annexin V staining after 48 h. Among the
three BCR-ABL1 pre–B lymphoblastic leukemia cell lines,
viability (mean of three experiments  SD) was 90.3% 
2.7% with nontargeting siRNAs and 18.6%  13.7% with
PLC1-specific siRNAs. Among four leukemia cell lines that
carry other gene rearrangements, viability was 84.3%  12.2%
with nontargeting siRNAs and 67.6%  16.9% with PLC1-
specific siRNAs. Unlike BCR-ABL1–negative leukemia cells,
silencing of PLC1 in BCR-ABL1 pre–B lymphoblastic leu-
kemia cells results in a fivefold reduction of viability. Thus,
PLC1 contributes to survival signaling specifically in BCR-
ABL1 pre–B lymphoblastic leukemia cell lines.
COOH-terminally truncated BTK functions as a link between 
full-length BTK and BCR-ABL1
BCR-ABL1–dependent phosphorylation of BTK suggests
that BTK represents a substrate of the BCR-ABL1 kinase.
However, previous work demonstrated that BCR-ABL1
cannot phosphorylate full-length BTK directly, but the
NH2-terminal BTK-SH3 domain fused to GST (26).
To determine how BCR-ABL1 can induce phosphory-
lation of full-length BTK, we studied whether full-length
BTK or BTK splice variants are part of the BCR-ABL1-sig-
nalosome. Using protein extracts of two BCR-ABL1
pre–B lymphoblastic leukemia cell lines, BCR-ABL1 signal-
ing complexes were immunoprecipitated with a BCR-spe-
cific antibody. Immunoprecipitation was controlled using
an anti-ABL1 antibody. Western blot showed that low
amounts of full-length BTK coimmunoprecipitates with
BCR-ABL1 (Fig. 6 A). As a control for quantitative distri-
bution of full-length BTK, BTKp65, and BTKp52 before
coimmunoprecipitation with BCR-ABL1, whole cell lysates
(WCLs) from two BCR-ABL1 leukemia cell lines were
subjected to Western blot (Fig. 6 A). Although full-length
BTK, BTKp65, and BTKp52 are expressed at similar levels in
the leukemia cells (WCL, Fig. 6 A), the amount of full-
length BTK that coimmunoprecipitated with BCR-ABL1
was 20-fold less than the amount of BTKp52 that coimmu-
noprecipitated with BCR-ABL1. Although BTKp65 is ex-
pressed clearly in the leukemia cells (WCL, Fig. 6 A), coim-
munoprecipitation of BTKp65 with BCR-ABL1 could not
be detected (Fig. 6 A).
Preferential binding of BCR-ABL1 to BTKp52 that
lacked the COOH terminus but retained the NH2-terminal
BTK-SH3 domain is consistent with previous findings that
demonstrated that BCR-ABL1 cannot directly phosphory-
late full-length BTK but can phosphorylate a BTK-SH3 do-
main-GST fusion molecule (26). However, binding of
BTKp52 to BCR-ABL1 also may be indirect in this case.
That the NH2-terminal BTK SH3 domain, but not full-
length BTK, can be phosphorylated readily by BCR-ABL1
suggests that the COOH terminus of BTK may interfere
with binding of BCR-ABL1 to BTK. Likewise, BTKp65
molecules that harbor an in-frame deletion but retain the
BTK COOH terminus do not immunoprecipitate with
BCR-ABL1. In this regard, the expression of truncated
BTK splice variants that lack the COOH terminus of BTK
may represent a mechanism to facilitate phosphorylation of
full-length BTK by BCR-ABL1. Because BTK molecules
also can self-associate through NH2-terminal SH3 domains
(27), BTKp52 may bind to BCR-ABL1 as well as to full-
length BTK and acts as link between the two kinases.
We next investigated whether full-length BTK can bind
to BTKp52. Using an antibody specific for COOH-terminal
BTK (only recognizes full-length BTK) for immunoprecipi-
tation and an NH2-terminal BTK antibody (recognizes full-
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length BTK and BTKp52) for subsequent Western blotting,
we observed that BTKp52 coimmunoprecipitates with full-
length BTK (Fig. 6 A). These findings suggest a role for
BTKp52 as a link between BCR-ABL1 and full-length BTK.
In this case, BTKp52 also would facilitate tyrosine phos-
phorylation of full-length BTK by BCR-ABL1. Therefore,
we tested whether silencing of BTKp52 in BCR-ABL1 pre–B
lymphoblastic leukemia cells results in decreased tyrosine
phosphorylation of full-length BTK. BCR-ABL1 pre–B
lymphoblastic leukemia cells were transfected with nontar-
geting or BTKp52-specific fluorescein-labeled siRNAs (Fig.
3). Fluorescein cells were sorted and analyzed for expres-
sion of tyrosine-phosphorylated BTK by Western blot (Fig.
6 B). Silencing of BTKp52 mRNA expression by siRNAs did
not interfere with mRNA expression of full-length BTK
(Fig. 3), yet tyrosine phosphorylation of full-length BTK
was decreased by 
90% (Fig. 6 B).
Given that BCR-ABL1 and full-length BTK cannot
bind directly to each other; BTKp52 can bind to BCR-ABL1
and full-length BTK; and expression of BTKp52 is required
for efficient tyrosine phosphorylation of full-length BTK, we
conclude that BTKp52 can act as a link between BCR-ABL1
and full-length BTK.
This is in agreement with previous work which sug-
gested that kinase-deficient BTK may act as a linker mole-
cule between upstream kinases (e.g., SYK) and downstream
effector molecules (e.g., PLC2; reference 11).
COOH-terminally truncated BTK can link full-length BTK to 
BCR-ABL1 through its SH3 domain
Based on this assumption, one would predict that the coex-
pression of BTKp52 with full-length BTK can facilitate the
interaction between BTK and BCR-ABL1, and hence, the
phosphorylation of downstream signaling molecules. To test
this possibility, BCR-ABL1, BTK, and its truncated variant,
BTKp52 were expressed in 293T embryonic kidney cells
alone, in various combinations, or in the presence of BTK
(LFM-A13) or BCR-ABL1 (STI571) kinase inhibitors. As a
readout of this experiment, tyrosine phosphorylation of
PLC1 and STAT5 was measured. According to a previous
study, 293T cells do not express BTK but do express PLC1
and STAT5 (28).
Figure 8. BTKp52, but not BTKp65, promotes cell survival, tyrosine 
phosphorylation of STAT5, and up-regulation of BCLXL. BCR-ABL1 
pre–B lymphoblastic leukemia cells (IX, Table I) were transfected with fluo-
rescein-labeled siRNA duplices against full-length BTK, BTKp52, or BTKp65 as 
described above (Fig. 3), and were analyzed by flow cytometry for annexin 
V expression (A). As a negative control, nontargeting siRNA duplices were 
used. Likewise, siRNA-treated leukemia cells were subjected to intracellular 
staining for tyrosine-phosphorylated STAT5 and analyzed by flow cytome-
try (B). For the analysis of mRNA levels of BCLXL, BCR-ABL1 pre–B lym-
phoblastic leukemia cells were transfected with a nontargeting siRNA duplex 
in the presence or absence of STI571 (for 12 h), as well as with siRNAs 
against full-length BTK, BTKp52, or BTKp65. 105 leukemia cells carrying fluo-
rescein-labeled siRNAs sorted by FACS and subjected to semiquantitative 
RT-PCR analysis for mRNA levels of BCLXL (C). mRNA levels for COX6B (C) 
and HPRT (Fig. 3) remained stable in all experiments.
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The expression of full-length BTK, BTKp52, or BCR-
ABL1 alone had no effect on tyrosine phosphorylation of
downstream molecules in general. However, to some extent,
single transfection with full-length BTK induced activation
of PLC1. Likewise, to some extent, BCR-ABL1 alone in-
duced tyrosine phosphorylation of STAT5 (Fig. 7, A and B);
this indicates that BCR-ABL1 can activate STAT5 partially
in the absence of BTK. Coexpression of BTKp52 which
lacked a functional kinase domain and BCR-ABL1 did not
increase tyrosine phosphorylation as compared with expres-
sion of BCR-ABL1 alone. However, coexpression of
BTKp52 with full-length BTK and BCR-ABL1 drastically
up-regulated PLC1 and STAT5 phosphorylation (Fig. 7
A). As assessed by intracellular staining, phosphorylated
PLC1 and STAT5 were distributed in the cytoplasm and
the nucleus, respectively (Fig. 7 B).
Activation of PLC1 and STAT5 upon triple transfec-
tion with full-length BTK, BTKp52, and BCR-ABL1 largely
was sensitive to BTK (LFM-A13) or BCR-ABL1 (STI571)
kinase inhibition. Hence, enzymatic activity of both kinases
is required for activation of PLC1 and STAT5. As a con-
trol, the enzymatic activity of BTK expressed in transfected
293T cells was confirmed in an in vitro kinase assay as de-
scribed in the Materials and methods section. The kinase ac-
tivity of BTK which was immunoprecipitated from 105
transfected 293T cells roughly was comparable to that of 25-
ng (0.008 U) recombinant BTK (Fig. 7 C).
Because BTK-SH3 domains can bind directly to BCR-
ABL1 (26) and also bind to proline-rich regions of other
BTK molecules (27), we tested whether the BTK-SH3 do-
main is sufficient to link full-length BTK to BCR-ABL1. In
fact, transfection of 293T cells with a vector encoding only
the BTK-SH3 domain had a similar effect compared with
transfection with BTKp52 comprising PH, TH, SH3, SH2
and a truncated kinase domain (Fig. 2 C). The SH3 domain
was sufficient to enable BCR-ABL1-driven activation of
PLC1 and STAT5 in the presence of active full-length
BTK (Fig. 7 A). We conclude that BTKp52, mainly through
its SH3 domain, can act as a linker between full-length BTK
and BCR-ABL1.
BTKp52 but not BTKp65 cooperates with full-length BTK to 
transduce BCR-ABL1–dependent survival signals
To clarify the specific contribution of BTKp52 and BTKp65
to BCR-ABL1 downstream survival signaling, annexin V
expression, STAT5 phosphorylation, and BCLXL mRNA
levels were measured in leukemia cells after transfection
with fluorescein-labeled siRNAs against BTKp52 and
BTKp65 and nontargeting siRNAs (Fig. 8, A–C). Transfec-
tion of leukemia cells with nontargeting siRNAs or siRNAs
against BTKp65 had no effect on viability as assessed by an-
nexin V staining (Fig. 8 A), tyrosine phosphorylation of
STAT5 (Fig. 8 B), and BCLXL mRNA levels (Fig. 8 C). In
contrast, siRNA-mediated silencing of BTKp52 induced
apoptosis in BCR-ABL1 pre–B lymphoblastic leukemia
cells to a similar extent as full-length BTK (Fig. 8 A). Like-
wise, silencing of full-length BTK or BTKp52 decreased ty-
rosine phosphorylation of STAT5 (Fig. 8 B) and reduced
mRNA levels of BCLXL in the leukemia cells (Fig. 8 C).
Collectively, these findings indicate that survival signals in
BCR-ABL1 pre–B lymphoblastic leukemia cells require
BTK activity, and BTKp52 to act as a link between full-
length BTK and BCR-ABL1.
Requirement of BTKp52 for BCR-ABL1–driven autonomous 
Ca2 signaling activity
Autonomous oscillatory Ca2 signals in BCR-ABL1 pre–B
lymphoblastic leukemia cells require kinase activity of
BCR-ABL1 and BTK (Fig. 5 A), as well as PLC activity
(9). Therefore, we investigated the impact of specific silenc-
ing of full-length BTK, BTKp52, and BTKp65 on PLC1
activation (Fig. 9 A). siRNA-mediated knockdown of full-
length BTK and BTKp52 expression similarly reduced ty-
rosine phosphorylation of PLC1, whereas siRNAs against
BTKp65 had no effect (Fig. 9 A). In agreement with this,
siRNA-mediated inhibition of full-length BTK or BTKp52
expression—but not expression of BTKp65—largely reduced
Figure 9. Specific silencing of BTK full-length or BTKp52 reduces 
PLC1 phosphorylation and autonomous Ca2 oscillations in BCR-ABL 
pre–B lymphoblastic leukemia cells. BCR-ABL1 pre–B lymphoblastic 
leukemia cells were transfected with nontargeting siRNAs or siRNAs 
against full-length BTK, BTKp52, or BTKp65, then subjected to intracellular 
staining for tyrosine-phosphorylated PLC1 and analyzed by flow-cytometry 
(A). Cytoplasmic Ca2 levels [nmol/l] were measured in single siRNA-
containing cells by confocal laser-scanning microscopy by continuous 
scanning for 6 min (B). Before analysis of Ca2 levels, leukemia cells carry-
ing fluorescein-labeled siRNAs were sorted by FACS. For each condition, 
50 individual cells were recorded. As a control, cytoplasmic Ca2 levels 
were measured in cells with nontargeting siRNAs (red line).
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the amplitude of autonomous Ca2 oscillations in BCR-
ABL1 pre–B lymphoblastic leukemia cells (Fig. 9 B). We
could not identify a specific function of BTKp65 with respect
to BCR-ABL1–mediated transformation in pre–B lympho-
blastic leukemia cells.
DISCUSSION
The leukemogenic BCR-ABL1 kinase mimics a constitu-
tively active pre–B cell receptor in pre–B lymphoblastic leu-
kemia cells. Although the leukemia cells frequently carry only
nonfunctional IGH-alleles (8), pre–B cell receptor signaling is
compromised even in the few cases in which the leukemia
cells express a pre–B cell receptor on their surface. Important
components of the pre–B cell receptor signaling cascade, in-
cluding SYK, SLP65, and BTK, are not phosphorylated in
response to pre–B cell receptor–engagement, and BTK is
constitutively phosphorylated by BCR-ABL1. BCR-ABL1–
dependent activation of BTK is critical for autonomous sur-
vival signals that otherwise would arise from the pre–B cell
receptor. We conclude that BTK activity is no longer re-
sponsive to pre–B cell receptor–dependent signals, but con-
tributes to multiple aspects of BCR-ABL1–driven survival
signaling in pre–B lymphoblastic leukemia cells.
Although BCR-ABL1 cannot interact with full-length
BTK directly (26), BCR-ABL1–induced aberrant splicing of
BTK premRNA leads to the expression of a truncated splice
variant of BTK that acts as a linker molecule between the
two kinases. Acting as a linker molecule, not only can trun-
cated BTKp52 facilitate BCR-ABL1–dependent activation of
full-length BTK but it can also facilitate BCR-ABL1–
dependent activation of downstream molecules, including
PLC1, STAT5, and BCLXL.
The interaction between BCR-ABL1 and BTK is critical
because inhibition of BCR-ABL1 by STI571 and interfer-
ence with BTK activity specifically induces apoptosis in
BCR-ABL1 B lymphoid leukemia cells. Because resistance
to STI571 is frequent in the therapy of this leukemia entity
(15), inhibition of BTK or its truncated splice variant poten-
tially represents a therapeutic approach to circumvent
STI571 resistance of BCR-ABL1 pre–B lymphoblastic leu-
kemia cells.
MATERIALS AND METHODS
Patient samples and cell lines. Clinical data on patient samples and cy-
togenetic data on cell lines used are summarized in Table I and are described
in detail in supplemental Materials and methods (available at http://
www.jem.org/cgi/content/full/jem.20042101/DC1). All studies on hu-
man materials were performed on samples provided in compliance with In-
stitutional Review Board regulations (Department of Hematology, Univer-
sity of Frankfurt).
Sequence analysis of BTK and semiquantitative RT-PCR. In a
search for BTK isoforms, fragments of the BTK cDNA were amplified cov-
ering the entire coding region using the PCR primer pairs listed in Table S1
(available at http://www.jem.org/cgi/content/full/jem.20042101/DC1.
BTK amplification products were sequenced as described previously (29).
Primers used for semiquantitative RT-PCR analysis of human BCR-ABL1,
BCLXL, GAPDH, HPRT, and COX6B transcripts are listed in Table S1.
Transient expression of BCR-ABL1 in pre–B lymphoblastic leuke-
mia cells. Pre–B lymphoblastic leukemia cells (697 cell line) that carry an
E2A-PBX1, but no BCR-ABL1, gene rearrangement were transfected tran-
siently by electroporation (250 V and 950 F) with pMIG-GFP or pMIG-
GFP BCR-ABL1 vectors that encoded GFP or GFP plus BCR-ABL1 as
described previously (30). For both transfections, GFP and GFP cells
were sorted after 24 h and subjected to mRNA isolation.
RNA interference with BTK and PLC1 expression. For each tar-
get, three different siRNA duplices were synthesized (MWG Biotech). Se-
quences of siRNA duplices are listed in Table S1. For knockdown of
PLC1 mRNA expression, a pool of three validated siRNAs which target
different PLC1 exons was used (Upstate). As a control, a nontargeting
siRNA duplex was used that does not match a known mRNA sequence.
All siRNA duplices were labeled with fluorescein using an siRNA labeling
kit (Ambion) according to the manufacturer’s protocol. BCR-ABL1 pre–B
lymphoblastic leukemia cells were transfected with a mixture of three fluo-
rescein-labeled siRNAs for each target sequence at a concentration of 100
nmol/l using oligofectamine in Opti-MEM1 medium (Invitrogen). After
24 h, leukemia cells were retransfected with labeled siRNAs and incubated
for an additional 24 h. Transfection efficiency was controlled by fluores-
cence microscopy and by FACS. The silencing effect of siRNAs for specific
BTK isoforms was controlled by RT-PCR analysis of BTK splice variants
in sorted of fluorescein cells. siRNA-containing fluorescein cells were
sorted using a FACStar 440 cell sorter. For each condition, 5  105 cells
were sorted and subjected to RNA isolation and cDNA synthesis.
Western blotting. For the detection of signaling molecules by Western
blot, antibodies against BTK, PLC1, PLC2, SLP65, and SYK (Cell Signal-
ing Technology), and phosphotyrosine-specific antibodies against BTKY223,
PLC1Y783, PLC2Y1217, SLP65Y96, and SYKY323 (Cell Signaling Technol-
ogy) were used with the WesternBreeze immunodetection system (Invitro-
gen). Mouse monoclonal antibodies against tyrosine-phosphorylated BTKY223
and BTKY551 were provided by O.N. Witte (University of California, Los
Angeles, CA).
Coimmunoprecipitation. For immunoprecipitation of BCR-ABL1 or
BTK, 1.7 mg protein lysate in a volume of 800 l was incubated with 30 l
rProtein G Agarose beads (Invitrogen) for 2 h at 4C on a shaker. The su-
pernatant was separated from the agarose beads and incubated with 6 g of
an antibody against BCR (Santa Cruz Biotechnology) or with 15 g of an
antibody against COOH-terminal BTK (provided by Owen N. Witte). Af-
ter 8 h, 30 l of agarose beads were added and incubation was continued
overnight. The agarose beads were washed twice with lysis buffer, resus-
pended in 35 l of lysis buffer, and subjected to Western blotting.
Flow cytometry. For FACS analysis of BCR-ABL1 pre–B lymphoblas-
tic leukemia cells, antibodies against tyrosine-phosphorylated BTKY223, ty-
rosine-phosphorylated PLC1Y783, and tyrosine-phosphorylated STAT5Y694
(Cell Signaling Technologies) were used. Apoptotic or dead cells were
identified by propidium iodide or PE-labeled annexin V (BD Biosciences).
As secondary antibody, anti–rabbit or anti–mouse IgG-Cy3 (Jackson Im-
munoResearch Laboratories) was used.
Immunofluorescence and confocal laser microscopy. Nuclear, cyto-
plasmic, or membrane localization of phosphorylated BTKY223, PLC1Y783,
and STAT5Y694 was analyzed using primary antibodies from Cell Signaling
Technology together with anti–rabbit IgG-Cy5 (Jackson ImmunoResearch
Laboratories) as secondary antibody. Cells were fixed with 0.4% paraformal-
dehyde and incubated for 10 min in 90% methanol on ice and subjected to
confocal laser-scanning microscopy as described previously (14).
Expression of BCR-ABL1, full-length BTK, BTKp52, and the BTK-
SH3 domain in 293T cells. 106 293T embryonic kidney cells were
plated on a 24-well plate 24 h before transfection. Different combinations
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of expression vectors were prepared as indicated and 5 g of each vector
was incubated with 8 l of FuGENE6 (Roche) and 50 l of serum- and
antibiotic-free RPMI 1640 medium for 15 min at room temperature. The
expression vector pMIG-bcr/abl for BCR-ABL1p210 (provided by D. Balti-
more, California Institute of Technology, La Jolla, CA) was used as de-
scribed previously (30). The expression vector pMIG-flagBtk for human
full-length BTK was generated by cloning of the human BTK cDNA into
the pMIG-R vector (30). For expression of BTKp52 (GenBank/EMBL/
DDBJ accession no. AJ888378), the expression vector pcDNA3.1 was used
with the directional TOPO Expression Kit (Invitrogen). For expression of
the BTK-SH3 domain, the pEBG BTK-SH3 vector (a gift from M. Bäck-
esjø, Karolinska Institute, Huddinge, Sweden) was used as described previ-
ously (26).
Measurement of Ca2 signals in BCR-ABL1 pre–B lymphoblastic
leukemia cells. Pre–B lymphoblastic leukemia cells that carry a BCR-
ABL1 gene rearrangement were cultured in the presence or absence of the
BCR-ABL1 inhibitor, STI571 (Novartis), or the BTK inhibitor, LFM-A13
(Calbiochem), for the times indicated. In a different set of experiments, cells
were transfected with fluorescein-labeled siRNA duplices and fluorescein
cells were sorted and conditioned in RPMI medium at 37C before mea-
surement of cytoplasmic Ca2 concentrations. Cells were washed and
stained with Fluo-3 dye (Calbiochem) for 30 min. Changes of cytosolic
Ca2 were measured by confocal laser microscopy (31). For each condition,
Ca2 release of 50 individual cells was recorded.
In vitro kinase assay. BTK that was immunoprecipitated from trans-
fected 293T cells was used in a kinase assay, including a Mg2/ATP cocktail
(100 mol/l) and a 61-kD fragment of PLC1 (Santa Cruz Biotechnology)
as a substrate of BTK. Equal amounts of PLC1 peptide (150 ng) and ATP
were incubated for 10 min at 30C with BTK immunoprecipitates from 105
transfected 293T cells; 25-ng active human recombinant BTK (Upstate)
was used as a positive control or 100 ng of a peptide corresponding to the
BTK-SH3 domain (Labvision; lacking kinase activity) was used as a nega-
tive control. The kinase activity of BTK that was immunoprecipitated from
5  105 transfected 293T cells was roughly comparable to that of 25-ng
(0.008 U) recombinant BTK (Fig. 7 C).
Online supplemental material. A detailed description of patient samples
and cell lines that were used in this paper is available as supplemental Mate-
rials and methods. Table S1 lists all PCR primers and siRNA duplices used.
Table S2 describes all aberrant splice variants of BTK amplified from BCR-
ABL1 pre–B lymphoblastic leukemia cells. Table S3 depicts SAGE-data
on mRNA levels of BCLX and BTK isoforms in normal B cell subsets and
BCR-ABL1 leukemia cells. Online supplemental material is available at
http://www.jem.org/cgi/content/full/jem.20042101/DC1.
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